Alpha 2.0
Login Register
» Articles » PMID: 6285357

[3H]nitrendipine-labeled Calcium Channels Discriminate Inorganic Calcium Agonists and Antagonists

Overview
Journal Proc Natl Acad Sci U S A
Specialty Science
Date 1982 Jun 1
PMID 6285357
Citations 51
Authors
R J Gould
K M Murphy
S H Snyder
Affiliations
Soon will be listed here.
Abstract

[3H]Nitrendipine binds with high affinity to brain membranes with a drug specificity indicating association with sites mediating the pharmacologic actions of dihydropyridine slow-calcium-channel antagonist drugs. In brain membranes, [3H]nitrendipine binding is absolutely dependent on the presence of calcium ions. Interactions of cation with [3H]nitrendipine binding sites correlate with their physiologic actions at voltage-dependent calcium channels. Ions such as strontium and barium, which mimic calcium physiologically, share the action of calcium in enhancing [3H]nitrendipine binding. Ions such as lanthanum an cobalt, which block the effects of calcium, can inhibit [3H]nitrendipine binding and block the stimulating actions of calcium. The ability to monitor the influence of ions on an agonist-antagonist continuum at [3H]nitrendipine binding sites provides a molecular probe to explore the regulation of cellular function by calcium and other cations.

Citing Articles

Discovery of New 3-(Benzo[]Thiophen-2-yl)Pyrrolidine-2,5-Dione Derivatives as Potent Antiseizure and Antinociceptive Agents-In Vitro and In Vivo Evaluation.

Rapacz A, Jakubiec M, Abram M, Jasinski J, Chrzan K, Gora M Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598442 PMC: 11597642. DOI: 10.3390/ph17111532.

Development of Novel Alaninamide Derivatives with Anticonvulsant Activity and Favorable Safety Profiles in Animal Models.

Abram M, Jakubiec M, Koczurkiewicz-Adamczyk P, Doroz-Plonka A, Rapacz A, Kaminski K Int J Mol Sci. 2024; 25(18).

PMID: 39337345 PMC: 11432405. DOI: 10.3390/ijms25189861.

Predicting therapeutic and side effects from drug binding affinities to human proteome structures.

Sawada R, Sakajiri Y, Shibata T, Yamanishi Y iScience. 2024; 27(6):110032.

PMID: 38868195 PMC: 11167438. DOI: 10.1016/j.isci.2024.110032.

In Vivo and In Vitro Characterization of Close Analogs of Compound KA-11, a New Antiseizure Drug Candidate.

Andres-Mach M, Zagaja M, Szala-Rycaj J, Szewczyk A, Abram M, Jakubiec M Int J Mol Sci. 2023; 24(9).

PMID: 37176010 PMC: 10179080. DOI: 10.3390/ijms24098302.

New Phenylglycinamide Derivatives with Hybrid Structure as Candidates for New Broad-Spectrum Anticonvulsants.

Jakubiec M, Abram M, Zagaja M, Andres-Mach M, Szewczyk A, Latacz G Cells. 2022; 11(12).

PMID: 35740990 PMC: 9221546. DOI: 10.3390/cells11121862.

References
1.
Reuter H . Divalent cations as charge carriers in excitable membranes. Prog Biophys Mol Biol. 1973; 26:1-43. DOI: 10.1016/0079-6107(73)90016-3. View
2.
Chang K, Jacobs S, Cuatrecasas P . Quantitative aspects of hormone-receptor interactions of high affinity. Effect of receptor concentration and measurement of dissociation constants of labeled and unlabeled hormones. Biochim Biophys Acta. 1975; 406(2):294-303. DOI: 10.1016/0005-2736(75)90011-5. View
3.
FLECKENSTEIN A . Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977; 17:149-66. DOI: 10.1146/annurev.pa.17.040177.001053. View
4.
Henry P . Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol. 1980; 46(6):1047-58. DOI: 10.1016/0002-9149(80)90366-5. View
5.
Antman E, Stone P, Muller J, Braunwald E . Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med. 1980; 93(6):875-85. DOI: 10.7326/0003-4819-93-6-875. View